Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.

Bastiaens L, Scott O, Galus J.

Psychiatr Q. 2019 Mar;90(1):41-46. doi: 10.1007/s11126-018-9602-7.

PMID:
30255422
2.

Atomoxetine for the Treatment of ADHD in Incarcerated Adolescents.

Jillani S, Patel P, Trestman R, Kamath J.

J Am Acad Psychiatry Law. 2016 Jun;44(2):158-63.

PMID:
27236169
3.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
4.

The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.

Perugi G, Vannucchi G.

Expert Opin Pharmacother. 2015;16(14):2193-204. doi: 10.1517/14656566.2015.1079620. Review.

PMID:
26364896
5.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

6.

Attention deficit/hyperactivity disorder in female offenders: prevalence, psychiatric comorbidity and psychosocial implications.

Rösler M, Retz W, Yaqoobi K, Burg E, Retz-Junginger P.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):98-105. doi: 10.1007/s00406-008-0841-8. Epub 2008 Sep 19.

PMID:
18806916
7.

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.

Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Pharmacoeconomics. 2012 Aug 1;30(8):e1-15. doi: 10.2165/11632920-000000000-00000.

8.

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.

Newcorn JH, Weiss M, Stein MA.

CNS Spectr. 2007 Aug;12(8 Suppl 12):1-14; quiz 15-6.

PMID:
17667893
9.

Adult ADHD Among NSW Prisoners: Prevalence and Psychiatric Comorbidity.

Moore E, Sunjic S, Kaye S, Archer V, Indig D.

J Atten Disord. 2016 Nov;20(11):958-967. Epub 2013 Oct 17.

PMID:
24134874
10.

Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.

Jain R, Katic A.

Prim Care Companion CNS Disord. 2016 Aug 18;18(4). doi: 10.4088/PCC.16r01979. Review.

11.
12.

When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.

Manor I, Rozen S, Zemishlani Z, Weizman A, Zalsman G.

Clin Neuropharmacol. 2011 Jul-Aug;34(4):148-54. doi: 10.1097/WNF.0b013e3182206dc1.

PMID:
21738027
13.

Screening for attention-deficit hyperactivity disorder and co-morbid mental disorders among prison inmates.

Einarsson E, Sigurdsson JF, Gudjonsson GH, Newton AK, Bragason OO.

Nord J Psychiatry. 2009;63(5):361-7. doi: 10.1080/08039480902759184.

PMID:
19247871
14.

Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.

Chen CY, Gerhard T, Winterstein AG.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):187-95. doi: 10.1089/cap.2008.096.

PMID:
19364296
15.

Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.

Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

CNS Drugs. 2013 Nov;27(11):943-53. doi: 10.1007/s40263-013-0102-x.

16.

Co-morbid psychiatric disorders among incarcerated ADHD populations: a meta-analysis.

Young S, Sedgwick O, Fridman M, Gudjonsson G, Hodgkins P, Lantigua M, González RA.

Psychol Med. 2015;45(12):2499-510. doi: 10.1017/S0033291715000598. Epub 2015 Apr 10.

17.

Assessment and treatment of correctional inmates with ADHD.

Appelbaum KL.

Am J Psychiatry. 2008 Dec;165(12):1520-4. doi: 10.1176/appi.ajp.2008.08060849. No abstract available.

PMID:
19047332
18.

Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Pérez de los Cobos J, Siñol N, Pérez V, Trujols J.

Br J Clin Pharmacol. 2014 Feb;77(2):337-56. doi: 10.1111/bcp.12045. Review.

19.

ADHD Medication and Substance-Related Problems.

Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, Sjölander A, Lichtenstein P, Larsson H, D'Onofrio BM.

Am J Psychiatry. 2017 Sep 1;174(9):877-885. doi: 10.1176/appi.ajp.2017.16060686. Epub 2017 Jun 29.

20.

Addiction severity pattern associated with adult and childhood Attention Deficit Hyperactivity Disorder (ADHD) in patients with addictions.

Fatséas M, Hurmic H, Serre F, Debrabant R, Daulouède JP, Denis C, Auriacombe M.

Psychiatry Res. 2016 Dec 30;246:656-662. doi: 10.1016/j.psychres.2016.10.071. Epub 2016 Nov 1.

PMID:
27842945

Supplemental Content

Support Center